Moreover, specific oncometabolites, such as 2-hydroxyglutarate (2-HG), in isocitrate dehydrogenase (IDH)-mutant cancers act as epigenetic modifiers and reinforce cancer-promoting programs (43, 46). This evidence concerns the gene IDH3A and cancer.